Adolor Corporation (NASDAQ:ADLR) is a biopharmaceutical company specializing in the discovery, development and commercialization of novel prescription pain management products. The Company's first product, ENTEREG® (alvimopan) was approved by the FDA and launched with Glaxo Group Limited in mid-2008. ENTEREG is indicated to accelerate the time to upper and lower gastrointestinal (GI) recovery following partial large or small bowel resection surgery with primary anastomosis. For more information on ENTEREG, including its full prescribing information, visit www.ENTEREG.com.
The Company’s research and development pipeline includes: two novel delta opioid receptor agonists, currently in mid-stage clinical development in collaboration with Pfizer Inc. for chronic pain; a peripheral mu opioid receptor antagonist entering development for chronic opioid bowel dysfunction (OBD); and several opioid and non-opioid discovery programs.
Adolor is:
-Committed to innovation, focused on invention
-Driven by imagination to meet unmet medical needs in pain management
The Company’s research and development pipeline includes: two novel delta opioid receptor agonists, currently in mid-stage clinical development in collaboration with Pfizer Inc. for chronic pain; a peripheral mu opioid receptor antagonist entering development for chronic opioid bowel dysfunction (OBD); and several opioid and non-opioid discovery programs.
Adolor is:
-Committed to innovation, focused on invention
-Driven by imagination to meet unmet medical needs in pain management
Phone: +234 704 387 4318
Founded date: 1993
Investors 2
| Date | Name | Website |
| - | InterWest ... | interwest.... |
| - | SpringRock... | springrock... |
Mentions in press and media 13
| Date | Title | Description |
| 09.08.2024 | The Rise of Blockchain Innovations: A New Era of Decentralization | The blockchain landscape is evolving rapidly. New technologies and platforms are emerging, reshaping how we interact with digital assets. The latest developments showcase a vibrant ecosystem, brimming with potential. This article explores k... |
| 08.08.2024 | Protocol Village: Nagdagdag ang Cubist ng Pangunahing Suporta sa Pamamahala para sa Bitcoin, Inilunsad ng Stork ang 'Open Data Market' | Huwebes, Agosto 8 Cubist, Blockchain Key Manager, Nagdaragdag ng Comprehensive Support para sa Bitcoin Transaction Signing Ang Cubist , na pinamumunuan ng co-founder at Carnegie Mellon University engineering Assistant Professor Riad Wahby ,... |
| 20.01.2014 | The 4 Winners of the Blue Button Innovation Challenge Changing the Face of Healthcare | In three days, 15 startups emerged, aimed at changing an industry that daily impacts every single individual. "What you guys are doing are transforming healthcare and changing lives," said Andrea Ippolito, co-leader of MIT Hacking... |
| 25.02.2013 | Cubist Announces Exclusive Option To Acquire Adynxx | |
| 04.12.2012 | New broad-spectrum antibiotic based on Nobel Prize-winning research reaches phase 3 | The drug has been tested in more than 1,200 patients in four phase 2 trials, where it’s shown promising results in the treatment of pneumonia, bronchitis and skin infections. It’s being developed in oral and IV formulations so that patients... |
| 24.10.2011 | Cubist Pharmaceuticals to buy Pennsylvania drug company for $190M | Cubist Pharmaceuticals (NASDAQ:CBST) has agreed to purchase Exton, Pennsylvania-based Adolor (NASDAQ:ADLR) in a $190 million deal. Adolor markets Entereg (alvimopan), a U.S. Food and Drug Administration-approved therapy that accelerates the... |
| 23.05.2008 | Lies, Damned Lies, and Statistics: The Definitive Rundown on New England Biotech | Share Share on Facebook Share on Twitter LinkedIn Email Reprints It’s official: 2007 rocked for New England biotech. Whether you look at IPOs, mergers, or venture activity, the region is consistently among the nation’s leaders. And on a per... |
| 26.12.2007 | Life sciences briefing: Wednesday, Dec. 26, 2007 | Romark Labs raises $18M for hepatitis drugs — Tampa, Fla.-based Romark Laboratories, a biotech developing drugs for hepatitis and other conditions, raised $18 million in a an institutional financing. D.E. Shaw Group provided the funding. Ro... |
| 22.10.2007 | All Sorts of Acquisitions, An Approval for Millennium, Venture Deals, and More | Share Share on Facebook Share on Twitter LinkedIn Email Reprints There was a lot of acquisition activity last week (not even counting the Biogen Idec excitement). Here’s more on that, along with the rest of the week’s news. —Lexington, MA-b... |
| 16.10.2007 | Cubist Takes Option to Acquire Illumigen | Share Share on Facebook Share on Twitter LinkedIn Email Reprints Lexington, MA-based Cubist Pharmaceuticals announced it will pay $4.7 million, plus another $1 million in research and operating costs, for an exclusive option to buy Seattle’... |
Show more